Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.
about
Targeting Forkhead Box M1 Transcription Factor in Breast Cancer.Sentinel lymph node B cells can predict disease-free survival in breast cancer patientsNeoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this FieldDevelopment of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX
P2860
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Neoadjuvant treatments in trip ...... re now and where we are going.
@en
Neoadjuvant treatments in trip ...... re now and where we are going.
@nl
type
label
Neoadjuvant treatments in trip ...... re now and where we are going.
@en
Neoadjuvant treatments in trip ...... re now and where we are going.
@nl
prefLabel
Neoadjuvant treatments in trip ...... re now and where we are going.
@en
Neoadjuvant treatments in trip ...... re now and where we are going.
@nl
P2093
P2860
P50
P356
P1476
Neoadjuvant treatments in trip ...... re now and where we are going.
@en
P2093
Claudia Omarini
Giorgia Guaitoli
Laura Cortesi
Stefania Pipitone
P2860
P304
P356
10.2147/CMAR.S146658
P407
P577
2018-01-15T00:00:00Z